ImmunoGen, Inc. (IMGN) Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update
8/2/2013 6:46:21 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) antibody-drug conjugate (ADC) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.
Help employers find you! Check out all the jobs and post your resume.
comments powered by